FY2026 EPS Estimates for CG Oncology Lowered by Analyst

Key Points

• Lifesci Capital has downgraded its FY2026 earnings per share estimate for CG Oncology to ($2.97), a significant decline from the previous estimate of ($2.04).
• CG Oncology reported a quarterly EPS of ($0.54), which fell short of analysts' expectations of ($0.49), highlighting ongoing financial challenges.
• Several analysts maintain a positive outlook with "buy" ratings for CG Oncology, although price targets vary, reflecting differing opinions on the stock's potential performance.

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Equities researchers at Lifesci Capital lowered their FY2026 earnings per share (EPS) estimates for shares of CG Oncology in a research report issued on Monday, September 15th. Lifesci Capital analyst S. Slutsky now anticipates that the company will earn ($2.97) per share for the year, down from their prior forecast of ($2.04). The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative return on equity of 19.37% and a negative net margin of 15,945.17%.

Several other analysts have also commented on CGON. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 target price on shares of CG Oncology in a report on Monday, September 8th. Jones Trading began coverage on CG Oncology in a research report on Monday, September 8th. They issued a "buy" rating and a $50.00 target price on the stock. The Goldman Sachs Group upgraded CG Oncology to a "strong-buy" rating and set a $40.00 target price on the stock in a research report on Thursday, July 10th. Wall Street Zen downgraded CG Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $56.00.

CG Oncology Stock Performance

CG Oncology stock traded down $1.92 during midday trading on Wednesday, hitting $36.90. 2,019,030 shares of the company were exchanged, compared to its average volume of 1,086,112. The firm has a market capitalization of $2.81 billion, a PE ratio of -20.85 and a beta of 0.87. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $40.47. The business has a fifty day simple moving average of $28.21 and a two-hundred day simple moving average of $25.94.

Hedge Funds Weigh In On CG Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Winthrop Capital Management LLC acquired a new position in CG Oncology during the 2nd quarter worth approximately $38,000. GF Fund Management CO. LTD. acquired a new position in CG Oncology during the 4th quarter worth approximately $41,000. CWM LLC increased its position in CG Oncology by 3,957.7% during the 1st quarter. CWM LLC now owns 2,110 shares of the company's stock worth $52,000 after purchasing an additional 2,058 shares during the period. GAMMA Investing LLC increased its position in CG Oncology by 1,051.0% during the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock worth $56,000 after purchasing an additional 2,102 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of CG Oncology by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company's stock worth $77,000 after acquiring an additional 398 shares during the period. Institutional investors and hedge funds own 26.56% of the company's stock.

Insider Activity

In other CG Oncology news, Director Hong Fang Song sold 100,000 shares of the company's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $27.80, for a total transaction of $2,780,000.00. Following the completion of the sale, the director directly owned 2,903,931 shares of the company's stock, valued at $80,729,281.80. This represents a 3.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James Mulay sold 27,015 shares of the company's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $31.53, for a total value of $851,782.95. The disclosure for this sale can be found here. Insiders sold 130,015 shares of company stock worth $3,722,883 over the last quarter. 7.40% of the stock is owned by insiders.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.